Can treating rheumatoid arthritis with disease‑modifying anti‑rheumatic drugs at the window of opportunity with tight control strategy lead to long‑term remission and medications free remission in real‑world clinical practice? A cohort study

Can treating rheumatoid arthritis with disease‑modifying anti‑rheumatic drugs at the window of opportunity with tight control strategy lead to long‑term remission and medications free remission in real‑world clinical practice? A cohort study


چاپ صفحه
پژوهان
صفحه نخست سامانه
چکیده مقاله
چکیده مقاله
نویسندگان
نویسندگان
دانلود مقاله
دانلود مقاله
دانشگاه علوم پزشکی تبریز
دانشگاه علوم پزشکی تبریز

نویسندگان: ساناز ابراهیمیان , آیدا مالک مهدوی , علیرضا خبازی اسکویی , مهرزاد حاج علیلوی بناب , امین سلامی

کلمات کلیدی: Disease-modifying anti-rheumatic drugs (DMARDs); Long-term remission; Real-world clinical practice; Rheumatoid arthritis; Window of opportunity.

نشریه: 55104 , 11 , 40 , 2021

اطلاعات کلی مقاله
hide/show

نویسنده ثبت کننده مقاله علیرضا خبازی اسکویی
مرحله جاری مقاله تایید نهایی
دانشکده/مرکز مربوطه بیماری های بافت همبند
کد مقاله 76788
عنوان فارسی مقاله Can treating rheumatoid arthritis with disease‑modifying anti‑rheumatic drugs at the window of opportunity with tight control strategy lead to long‑term remission and medications free remission in real‑world clinical practice? A cohort study
عنوان لاتین مقاله Can treating rheumatoid arthritis with disease‑modifying anti‑rheumatic drugs at the window of opportunity with tight control strategy lead to long‑term remission and medications free remission in real‑world clinical practice? A cohort study
ناشر 6
آیا مقاله از طرح تحقیقاتی و یا منتورشیپ استخراج شده است؟ بلی
عنوان نشریه (خارج از لیست فوق)
نوع مقاله Original Article
نحوه ایندکس شدن مقاله ایندکس شده سطح یک – ISI - Web of Science
آدرس لینک مقاله/ همایش در شبکه اینترنت

خلاصه مقاله
hide/show

Objective The aim of this retrospective study is to compare the results of starting rheumatoid arthritis (RA) treatment with tight control strategy in the window of opportunity and later phases of the disease in real-world clinical practice. Methods In this cohort, 609 RA patients were divided into three groups: (i) very early treatment (VET): ≤ 3 months; (ii) early treatment (ET): 3–12 months; and (iii) late treatment (LT) > 12 months after the onset of the disease. Four levels of remission were defined: (i) sustained remission on treatment, (ii) sustained glucocorticoids free remission, (iii) sustained disease-modifying anti-rheumatic drugs (DMARDs) free remission, and (iv) long-term remission. Outcome was assessed based on the number of patients in sustained or long-term remission and patients with poor joint outcome and systemic involvement. Results There were no significant differences in the remission rate between the groups. Time to sustained remission in VET group was shorter than ET and LT groups. There were no significant differences in the rate and duration of prednisolone discontinuation in the studied groups. DMARDs were discontinued in VET, ET, and LT groups in 8.7%, 10.2%, and 7% of the patients, respectively. Poor joint outcome occurred in 33.2%, 50.5%, and 59.4% of the patients in the VET, ET, and LT groups, respectively. Remission induction in the first year of the treatment was associated with long-term remission in the VET, ET, and LT groups. Conclusions Medications free remission in RA is rare, and although treatment with DMARDs within 3 months of the onset of the disease can prevent joint damage, it cannot lead to long-term remission and discontinuation of medications.

نویسندگان
hide/show

نویسنده نفر چندم مقاله
ساناز ابراهیمیاناول
آیدا مالک مهدویسوم
علیرضا خبازی اسکوییپنجم
مهرزاد حاج علیلوی بنابششم
امین سلامیدوم

لینک دانلود مقاله
hide/show

نام فایل تاریخ درج فایل اندازه فایل دانلود
Ebrahimian2021_Article_CanTreatingRheumatoidArthritis.pdf1400/07/27600250دانلود